Technology provider Celoxica continues to focus on ultra-low latency solutions and has announced its latest addition to its hardware accelerated market data products with the launch of the Generic Book Accelerator (GBA) product line for the US markets.
The GBA delivers unique performance advantage maintaining order books on a field-programmable gate array (FPGA) board and distributes the five best limits to consuming applications delivering deterministic wire to wire latency of 1 microsecond and eliminating performance spikes.
Combined with GBA, Symbol Filtering also reduces the required system bandwidth ensuring only relevant market data is sent to consuming applications and therefore guarantees optimized memory and compute profile for subscribing applications and significant reductions in infrastructure cost.
Market Trading Ideas for May 10-14Go to article >>
The introduction of the GBA demonstrates the company’s interest in maintaining market share within the high-frequency trading segment, as the company considers this an important target market along with proprietary trading groups, investment banks and execution services providers. Earlier this year, Celoxica launched a hardware-accelerated futures trading platform with the same criteria in mind.
$3 Million Funding Round Completed
In a corporate statement from Celoxica issued on May 17th, Chairman and CEO Jean Marc Bouhelier explained: “In a market where margins are being continually squeezed and where performance remains of paramount importance, our goal is to deliver state-of-the art technology solutions that help our clients address these challenges whilst reducing their total cost of ownership.”
Mr. Bouhelier further stated that “Celoxica’s ability to offer market data distribution on a single FPGA based card, utilizing standard servers and reducing collocation infrastructure, whilst ensuring the best possible performance, allows us to successfully meet these goals”
In accordance with the company’s development of new low latency solutions, Celoxica has gained $3 million in funding from a series of investors led by Oxford Capital Partners in the UK, in addition to which all existing institutional investors participated. This injection of capital will be used to expand Celoxica’s sales and marketing presence in the US and Europe and for continued investment in the technology roadmap. In adding Celoxica to its portfolio, Oxford Capital Partners shows that it is also keen to invest in financial technology companies in addition to its existing client base which is made up largely of technology companies for the science and engineering industries.